-

Emergent BioSolutions to Participate in Jefferies Global Healthcare Conference

GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Jefferies Global Healthcare Conference in London, November 16-19, 2026.

Management will present via webcast on November 18 at 8:00am – 8:25am UTC/GMT (3:00am ET). A replay of the presentation will be available on the webcast page linked above for approximately three months. Visit Emergent’s Investor Relations page to learn more. Please contact a conference representative to request a one-on-one meeting.

About Emergent BioSolutions

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Contacts

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

Industry:

Emergent BioSolutions Inc.

NYSE:EBS
Release Versions
English

Contacts

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

Social Media Profiles
Emergent BioSolutions Instagram
Emergent BioSolutions LinkedIn
Emergent BioSolutions Podcast
Emergent BioSolutions Countermeasures
Emergent BioSolutions X
More News From Emergent BioSolutions Inc.

Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War (DoW). The first delivery, which is valued at approximately $7.4 million, will begin this year, and remaining deliveries are expected in 2027. This order is under Emergent’s existing indefinite-delivery/...

Emergent Biosolutions Reports Third Quarter 2026 Financial Results

GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2026. “Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation,” said Joe Papa, president and chief executive of...

Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl

GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer, will retire from the Company effective December 31, 2026. Frank Vargo, vice president, treasurer, will assume the role of interim chief financial officer effective January 1, 2027. To support a seamless transition, Rich will serve as a senior executive advisor from January 1 through March 31, 2027. “On behalf of the Board of Direc...
Back to Newsroom